Table 1A.

miRNA in pre-clinical and clinical trials for regenerative medicine.

Agent	Method of administration	Therapeutic effect	Clinical trial	BioPharmaceutical company	References
miR-29 mimics MRG-201	Direct skin injection	Anti-fibrous scar formation	Phase I	miRagen Therapeutics	ClinicalTrials.gov identifier: NCT02603224
LNA-anti-miR-208 MGN-9103	Intravenous injection	Treatment of chronic heart failure, preventing hypertrophy, fibrosis and pathological remodeling	Pre-clinical trial	miRagen Therapeutics	Montgomery et al., 2011; Eding et al., 2017
LNA-anti-miR-15 family MGN-1374	Intravenous injection	Post-myocardial infarction remodeling, enhances cardiomyocytes proliferation	Pre-clinical trial	miRagen Therapeutics	Hullinger et al., 2012
2′Ome anti-miR-21 RG-012	Subcutaneous injection	Alport syndrome, decreases renal fibrosis progression	Phase II	Regulus Therapeutics	ClinicalTrials.gov identifier: NCT02855268
2′MOE, 2′fluoro-sugar modified nucleosides anti-miR-155	Intraperitoneal injection	Amyotrophic lateral sclerosis	Preclinical trial	Regulus Therapeutics	Koval et al., 2013